Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain
March 13 2017 - 7:30AM
Brill Pharma S.L. to also serve as agent
in price negotiations with the Spanish Ministry of
Health
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical
company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals, today
announced that Alimera Sciences Limited, its European subsidiary
based in London, has signed an exclusive agreement with Brill
Pharma S. L. (Brill Pharma), Barcelona, Spain, for distribution of
ILUVIEN® in the Kingdom of Spain, Alimera's sustained release
intravitreal injection for the treatment of diabetic macular edema.
Under the terms of this agreement, Brill Pharma will handle
promotion, marketing and commercial activities in Spain for
ILUVIEN. In addition, Brill will negotiate with the Spanish
Ministry of Health on the appropriate confidential net price for
reimbursement of ILUVIEN within the Spanish National Health System,
as well as on the public price.
“As a continuous microdosing treatment that lasts for up to
three years, ILUVIEN can make a major difference to patients with
DME in Spain,” said Dan Myers, President and Chief Executive
Officer of Alimera. “With the help of Brill Pharma's experienced
team, we expect to reach Spanish patients and their physicians with
a truly innovative product that can consistently treat their
disease every day and markedly improve their quality of
life.”
“Spain has a strong tradition in the use of corticosteroids
being one of the largest markets in Europe. The introduction of
ILUVIEN will represent a substantial improvement in the long term
management of the pathology and the quality of life of a
significant number of patients. Brill Pharma will be the first
pharmaceutical company with Spanish capital, marketing an
innovative intravitreal product in diabetic macular edema,” said
Dr. Jordi Martinez Rotllan, Chief Executive Officer of Brill
Pharma.
About ILUVIEN
www.ILUVIEN.com.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant indicated in the E.U. to
treat vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. Each ILUVIEN
implant with its continuous microdosing is designed to release
submicrogram levels of fluocinolone acetonide, a corticosteroid,
for 36 months, enabling the physician to treat the disease
consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company
that specializes in the research, development and commercialization
of prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
Alimera’s commitment to retina specialists and their patients is
manifest in Alimera’s product and development portfolio designed to
treat early- and late-stage diseases. For more information, please
visit www.alimerasciences.com.
About Brill Pharma S. L.
Brill Pharma, the Spanish subsidiary of Bristol Laboratories
U.K., is based in Barcelona, Spain and was established in September
2012. It markets innovative products in ophthalmology, is already
ranked fourth in this specific segment of the Spanish pharma market
and was recently recognized as the fastest growing Spanish pharma
company in its segment. The company employs more than 60 medical
representatives covering Spain. For further details, please visit
www.brillpharma.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, that Alimera believes it will
reach Spanish patients and physicians with Brill Pharma’s team.
Such forward-looking statements are based on current expectations
and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause
actual results to differ materially from those projected in its
forward-looking statements. Meaningful factors which could cause
actual results to differ include, but are not limited to, Brill
Pharma’s ability to launch ILUVIEN in 2017 in Spain, Brill Pharma’s
ability to successfully negotiate a price for ILUVIEN with the
Spanish Ministry of Health, Brill Pharma’s ability to provide
adequate promotion, marketing and commercial support for ILUVIEN,
physician’s in Spain will acceptance ILUVIEN for use with their DME
patients, and ILUVIEN acceptance by various institutions in the
Spain, as well as other factors discussed in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Alimera’s Annual Report on Form
10-K for the year ended December 31, 2016, which is on file
with the Securities and Exchange Commission (SEC) and
available on the SEC’s website at www.sec.gov.
In addition to the risks described above and in Alimera’s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other filings with the SEC, other
unknown or unpredictable factors also could affect Alimera’s
results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Alimera. Therefore, no assurance
can be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely too
heavily on the forward-looking statements Alimera makes or that are
made on its behalf. These forward-looking statements speak only as
of the date of this press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024